In the framework of the cooperation, which starts September 1, Goodwill Pharma will take over the distribution and promotion of two new products for the treatment of asthma from Novartis Hungária, according to state news wire MTI.

The move will give Goodwill Pharma a presence in new therapy areas and could have a “significant impact” on its future revenue and earnings, the company said.

Goodwill Pharma wants to see the cooperation extended to the regional level in the long term and expanded to the area of R&D, too, it added.

Goodwill Pharma’s shares are listed on the bourse’s Xtend platform tailored to SMEs.